Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Prime Medicine typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers and management commentary.

Prime Medicine has exhibited significant volatility around earnings releases, with an average absolute Day 0 move of 6.66% and an average Day +1 move of 5.19%. The Day 0 range averages 10.05%, while the Day +1 range averages 11.17%, indicating substantial intraday swings as investors digest results and guidance.

The most recent earnings release on August 6, 2026, saw a relatively modest 4.22% decline on Day 0, followed by a 4.41% gain on Day +1, suggesting initial caution gave way to a more positive assessment. However, earlier reports showed more dramatic moves—the March 2026 release triggered a 9.23% Day 0 decline, while the November 2025 report produced a 7.48% Day +1 drop.

The pattern suggests that Prime Medicine's post-earnings moves are driven more by forward-looking catalysts and pipeline updates than by the quarterly loss figures themselves. Given the company's recent clinical milestones and the upcoming 2027 data readouts, this quarter's reaction will likely hinge on management's commentary about trial enrollment progress, regulatory interactions, and cash deployment strategy rather than the actual EPS beat or miss.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 10.84% (±$0.43) for the November 20, 2026 expiration, which is moderately higher than the historical average absolute Day 0 move of 6.66% but slightly lower than the average Day 0 range of 10.05%. This suggests options traders are anticipating above-average volatility for this release, likely reflecting heightened uncertainty around the company's clinical progress updates and cash deployment plans following the recent capital raise.

Part 3: What Analysts Are Saying

Prime Medicine enjoys strong analyst support with a consensus rating of 4.60 out of 5.00, reflecting overwhelmingly bullish sentiment. The analyst community consists of 12 Strong Buy ratings, 0 Moderate Buys, and 3 Hold ratings, with no Sell or Strong Sell recommendations among the 15 analysts covering the stock. This rating has remained unchanged over the past month, indicating stable conviction.

The average price target stands at $7.02, implying 80.5% upside from the current price of $3.89. Price targets range from a low of $4.25 to a high of $11.00, with the wide spread reflecting differing views on the probability of clinical and regulatory success. The high target of $11.00 suggests some analysts see substantial value if Prime Medicine successfully executes on its BLA submission for PM359 and delivers positive data from its liver programs in 2027.

Analyst sentiment has remained unchanged according to the precomputed trend, suggesting that recent clinical milestones and the capital raise have been largely anticipated by the Street. The concentration of Strong Buy ratings indicates that most analysts view Prime Medicine's Prime Editing platform as differentiated within the gene editing space, with the potential to address large-market genetic diseases where current treatment options are limited. The absence of any Sell ratings underscores the view that the company's clinical progress and partnership with Bristol Myers Squibb provide meaningful validation of the technology.

Part 4: Technical Picture

Prime Medicine's technical setup heading into earnings shows improving momentum with the Barchart Technical Opinion registering an 88% Buy signal, up from a 72% Sell signal just one month ago. This dramatic reversal reflects the stock's recent strength following clinical milestones and the capital raise announcement. The signal held steady at 88% Buy over the past week, indicating sustained bullish momentum.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum is positive but not overwhelming, likely reflecting some profit-taking after the recent rally
• Medium-term (100% Buy): Strong buy signal indicates robust momentum in the intermediate timeframe, supported by the stock's move above key moving averages
• Long-term (100% Buy): Strong buy signal reflects sustained upward trend over the longer-term horizon, validating the multi-month recovery from earlier lows

Trend Characteristics: The combination of Good strength and Average direction suggests the stock is in a solid uptrend with moderate consistency, providing a generally supportive backdrop for the earnings release though not without some volatility risk.

The stock is currently trading at $3.89, positioned above the 50-day ($3.69), 100-day ($3.53), and 200-day ($3.50) moving averages, confirming the longer-term uptrend. However, it sits below the 5-day ($4.21), 10-day ($4.42), and 20-day ($4.26) moving averages, indicating some recent pullback from the post-announcement highs reached in early November.

This technical setup suggests the stock has consolidated after its sharp rally following the Wilson disease dosing announcement and capital raise. The pullback to support at the 50-day moving average could provide a constructive entry point for investors who believe the clinical catalysts justify the valuation. However, the stock's high volatility (167.29% average) and the gap between current price and short-term moving averages indicate that a disappointing earnings report or cautious guidance could trigger a test of the $3.50-$3.69 support zone. Conversely, positive commentary on trial enrollment and regulatory progress could propel the stock back toward the $4.35-$4.42 resistance area.